Healthcare entity
Of the tracked stories, 3 of 3 also mention Johnson & Johnson, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 4.2 for the same window. market-trends accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Johnson & Johnson, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 4.2 for the same window. market-trends accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Across a 136-day span, the pace is roughly 0.2 stories per week. At 6.3, the average consequence score sits above the same-window beat average of 6.2. Kenvue appears in 3 tracked Healthcare stories published from March 12, 2026 through July 25, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 564 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kenvue. Shared-story counts are live from our verified record — not editorial picks.
The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Source: The Motley Fool · fool.com
Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Source: finance.yahoo.com · insidermonkey.com
Kenvue is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
